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Background: The European Organization for Research and Treatment of Cancer Quality of Life Brain Cancer
Module has been translated into Korean, but to date, its reliability and validity have been evaluated in a pilot study
alone. The European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire is,
overall, a valid instrument to assess the health-related quality of life in Korean cancer patients, although its reliability
and validity have not yet been evaluated in patients with brain tumors. This study aimed at evaluating the
psychometric properties of these instruments in patients with brain tumors.
Findings: The 2 instruments were used for 307 Korean patients with brain tumors. Multi-trait scaling confirmed the
scale structure of the instruments with good item convergent and discriminant validity. The reliability was
acceptable for all scales except for cognitive functioning and nausea and vomiting. The instruments could be used
to distinguish between clinically distinct groups of patients.
Conclusions: The study findings indicate that the instruments are valid and suitable for the assessment of the
health-related quality of life in patients with brain tumors as well as in those with primary brain cancer.
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Despite improvements, many treatments for brain tu-
mors are not curative and these patients have a poor
prognosis. In addition, such treatments may be neuro-
toxic and, thus, negatively affect patient health-related
quality of life (HRQOL). Therefore, the use of well-
validated instruments when assessing the HRQOL of pa-
tients with brain tumors is particularly important. Most
HRQOL instruments were developed in English for a
predominantly English-speaking population. The European
Organization for Research and Treatment of Cancer brain
cancer module (EORTC QLQ-BN20) has previously been
tested in English-speaking patients and was shown to have
adequate psychometric properties [1]. The QLQ-BN20* Correspondence: jhkim1@amc.seoul.kr
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reproduction in any medium, provided the orwas translated into Korean by the EORTC group [2],
and its reliability and validity have been evaluated, al-
though only in a pilot study. The standard Korean ver-
sion of EORTC Quality of Life Core Questionnaire
(QLQ-C30) is, overall, a valid instrument for the assess-
ment of HRQOL in Korean patients with breast, stom-
ach, colon, and rectal cancers [3], although its reliability
and validity have not yet been specifically evaluated in
patients with brain tumors. Hence, the purpose of the
current study was to examine the validity and reliability
of the Korean version of the QLQ-BN20 and QLQ- C30
in patients with brain tumors.
Methods
Sample and setting
This study used a prospective, descriptive cross-sectional
design in which the convenience sampling was per-
formed at a tertiary-care university hospital in Seoul,
Korea. To be included in the study, patients had to bel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Socio-demographic and clinical characteristics
(N=307)
Variable Mean (SD, range) or N (%)





Middle school or less 77 (25.1)
High school 104 (33.9)
College 105 (34.2)











Surgery only 177 (57.7)





KPS Karnofsky performance scale, CTx chemotherapy, RTx radiation therapy.
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histologically verified brain tumor. Patients who had not
undergone surgery or those with metastatic brain tumors
were excluded. The study was approved by the institu-
tional review board of Asan Medical Center. Written in-
formed consent was obtained from all patients or their
legally authorized representative.
Instruments
The EORTC QLQ-BN20 is a 20-item questionnaire
grouped into 4 domains and 7 single items [1], while the
QLQ-C30 comprises a 30-item questionnaire. Raw
scores were standardized by linear transformation so
that the final scores were in the range of 0 –100. Higher
scores on the global QOL and functional scales repre-
sent a better QOL, whereas high symptom scale scores
indicate significant symptoms or greater difficulty.
Statistical analysis
Multi-trait scaling was employed to examine the scale
structure of the instruments. Item-scale correlations ≥
0.40 were considered to validate item convergent. Item-
scale discriminant validity was examined by comparing
the correlation of each item with its own scale versus
that with other scales. We expected a high correlation
between items (2 standard errors) with their own scale
rather than with other scales. The internal consistency
reliability of the instruments was estimated using
Cronbach’s alpha coefficient (α). Values of α ≥ 0.70 were
considered acceptable for group comparisons.
The known group validities were tested by comparing
the score of the Korean version of the QLQ-BN20 and
QLQ-C30 between patient groups. First, we hypothe-
sized that patients with a high performance status
(Karnofsky performance scale [KPS] score > 70) would
report lower levels of symptoms and a better QOL than
patients with a low performance status (KPS score ≤ 70).
Second, patients with glioma were expected to report a
higher level of symptoms than patients with meningi-
oma. Finally, patients who received adjuvant therapy
(chemotherapy, radiation therapy, or both) were expected
to report a higher level of future uncertainty than patients
who underwent surgery alone.
Construct validity was then examined by calculating
the correlations between the multi-item scales of the
QLQ-BN20 and QLQ-C30. We expected moderate cor-
relations between future uncertainty and emotional
functioning, visual disorder and cognitive functioning,
motor dysfunction and physical functioning, and com-
munication deficit and social functioning (r > 0.40).
We used SPSS 20.0 (SPSS Inc., Chicago, IL, USA) for
data analysis. Values of p < 0.05 were considered statis-
tically significant. Missing data were excluded from the
analysis.Results
Of 350 invited patients, 317 (90.6%) agreed to participate,
and a total of 307 (87.7%) useful questionnaires were
analysed. The mean age was 47.95 ± 13.64 years (range,
18–81 years). Fifty-seven percent of the patients were
women. Most patients were married (72%), and 37.5% had
completed college or graduate school. Gliomas (39.7%)
constituted the most frequent tumor type. More than half
of the patients underwent surgery alone (Table 1).
Scale reliability and scale structures
As shown Table 2, with the exception of the cognitive
functioning (0.60) and nausea and vomiting scales (0.64),
most of the multi-item scales of the QLQ-C30 and the
all scales of the QLQ-BN20 met the minimal standard of
reliability (α > 0.70).
The all-item scale of the QLQ-C30 correlated with its
own scale with a value of r ≥ 0.50, corrected for overlap,
and met the recommended psychometric standards.
Item-scale correlations of the QLQ-BN20 indicated that
Table 2 Scale reliability and structures
Mean (SD) Cronbach’s alpha Number of items Item-own scale correlation Item-other scale correlation
QLQ-C30
Functional scales
Physical functioning 71.16 (24.94) .87 5 0.55–0.90 0.16–0.55
Role functioning 69.74 (31.43) .89 2 0.93–0.94 0.25–0.69
Emotional functioning 71.51 (23.81) .87 4 0.79–0.87 0.27–0.56
Cognitive functioning 69.82 (25.80) .60 2 0.77–0.87 0.23–0.55
Social functioning 71.73 (30.72) .85 2 0.90–0.94 0.28–0.50
Global quality of life 54.19 (25.18) .88 2 0.94–0.94 0.29–0.50
Symptom scales/items
Fatigue 37.42 (23.04) .77 3 0.76–0.87 0.27–0.62
Nausea and vomiting 11.67 (17.53) .64 2 0.66–0.94 0.19–0.38
Pain 25.11 (26.93) .81 2 0.89–0.91 0.26–0.55
Dyspnea 20.37 (26.22) 1 1.00 0.30-0.51
Sleep disturbance 25.08 (31.61) 1 1.00 0.27–0.44
Appetite Loss 16.94 (24.90) 1 1.00 0.21–0.42
Constipation 17.10 (25.78) 1 1.00 0.14–0.25
Diarrhea 12.46 (22.57) 1 1.00 0.12–0.20
Financial difficulty 31.38 (35.19) 1 1.00 0.24–0.63
QLQ-BN20 scales
Future uncertainty 34.38 (23.67) .80 4 0.72–0.84 0.21–0.47
Visual disorder 27.27 (28.22) .83 3 0.73–0.90 0.19–0.36
Motor dysfunction 29.14 (28.92) .85 3 0.81–0.85 0.25–0.49
Communication deficit 22.41 (27.82) .90 3 0.84–0.92 0.18–0.50
QLQ-BN20 single items
Headache 33.44 (31.07) 1 1.00 0.30–0.41
Seizure 9.84 (23.06) 1 1.00 0.13–0.32
Drowsiness 43.32 (28.03) 1 1.00 0.26–0.42
Hair loss 21.57 (31.01) 1 1.00 0.00–0.26
Itchy skin 16.61 (25.05) 1 1.00 0.16–0.26
Weakness of legs 35.42 (33.27) 1 1.00 0.28–0.73
Bladder control 21.39 (30.88) 1 1.00 0.28–0.39
QLQ-C30 Quality of Life Core Questionnaire, QLQ-BN20 Quality of Life Questionnaire Brain Cancer Module.
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own scale (range, 0.72–0.92) than with other scales
(range, 0.18–0.50).
Clinical validity
As hypothesized, patients with higher KPS scores had
significantly better functioning and lower symptom
scores on all of the QLQ-C30 and QLQ-BN20 multi-
item scales than patients with lower KPS scores (p <
0.001–0.005, Table 3). Patients with glioma had signifi-
cantly lower physical, cognitive, and social functioning
scores as well as higher future uncertainty, motor dys-
function, and communication deficits than patients with
meningioma (p < 0.001–0.02). Patients who underwentsurgery plus adjuvant therapy reported lower functioning
(p < 0.001–0.03) and poor QOL (p = 0.01), but higher
future uncertainty (p = 0.02) and great communication
deficits (p = 0.03) than those who underwent surgery
alone. The 4 scales of the QLQ-BN20 were moderately
correlated with some of the QLQ-C30 scales as hypothe-
sized (r = −.410 – -.642, Table 4).
Discussion
The validity and reliability of the EORTC QLQ-BN20
and QLQ-C30 have been shown in studies across various
countries [4,5]. Here we present the results of a study
using the Korean version of the QLQ-BN20 and QLQ-
C30 in patients with brain tumors.
Table 3 Mean scores (standard deviation) of clinically distinct groups
Performance status Tumor type Treatment modality
KPS≤70 KPS>70 p* Glioma Meningioma Others p† OP only OP+adjuvant therapy p*
QLQ-C30
PF 29.8 (27.4) 76.4(19.0) <.001 66.2 (29.0) 75.1 (20.0) 73.7 (22.8) .02a 73.8 (22.2) 67.6 (27.9) .11
RF 27.3 (31.1) 74.9 (27.3) <.001 64.5 (35.7) 74.5 (24.7) 71.5 (31.6) .05 71.8 (27.8) 66.9 (35.7) .84
EF 56.2 (26.6) 73.5 (22.7) <.001 68.4 (24.8) 74.1 (20.6) 72.9 (26.0) .18 71.2 (24.1) 71.9 (23.5) .89
CF 42.9 (30.3) 73.3 (23.0) <.001 64.1 (27.7) 73.2 (24.6) 74.2 (22.7) .008b 72.3 (25.3) 66.4 (26.2) .03
SF 36.3 (32.7) 76.2 (27.4) <.001 63.6 (33.6) 81.0 (26.4) 71.9 (29.4) <.001c 77.2 (28.2) 64.2 (32.5) <.001
QOL 29.4 (22.3) 57.3 (23.8) <.001 50.8 (26.3) 58.1 (23.9) 54.1 (24.6) .09 57.3 (24.7) 50.0 (25.4) .01
FA 56.5 (24.2) 35.0 (21.7) <.001 40.4 (25.6) 34.2 (20.4) 37.3 (21.9) .13 36.2 (21.6) 39.2 (24.8) .24
NV 21.4 (25.1) 10.4 (15.9) .005 13.9 (18.7) 9.0 (14.4) 11.8 (19.2) .12 10.9 (17.9) 12.7 (17.0) .05
PA 51.4 (29.8) 21.7 (24.6) <.001 26.2 (29.6) 23.7 (24.0) 25.2 (26.6) .79 25.8 (26.3) 24.2 (27.9) .36
QLQ-BN20
FU 47.1 (26.6) 32.7 (22.8) .002 38.5 (24.2) 28.2 (21.1) 36.5 (24.7) .003d 32.0 (23.8) 37.5 (23.3) .02
VD 40.3 (31.4) 25.6 (27.4) .002 22.3 (26.2) 30.6 (27.3) 30.5 (31.5) .05 29.1 (29.4) 24.8 (26.4) .23
MD 73.7 (29.4) 23.4 (23.3) <.001 34.2 (32.6) 23.4 (23.0) 29.2 (28.9) .02e 26.9 (26.3) 32.2 (32.0) .33
CD 47.7 (34.5) 19.2 (25.2) <.001 30.1 (31.4) 16.0 (23.4) 19.1 (24.7) <.001f 19.3 (25.9) 26.6 (29.8) .03
* p-value was calculated by Mann–Whitney U test.
†p-value was calculated by ANOVA.
a, c Post-hoc test by Sheffe; glioma<meningioma.
b Post-hoc test by Sheffe; glioma<meningioma, glioma<others.
d, e, f Post-hoc test by Sheffe; glioma>meningioma.
KPS Karnofsky performance scale, OP operation, QLQ-C30 Quality of Life Core Questionnaire, PF physical functioning, RF role functioning, EF emotional functioning,
CF cognitive functioning, SF social functioning, FA fatigue, NV nausea and vomiting, PA pain, QLQ-BN20 Quality of Life Questionnaire Brain Cancer Module,
FU future uncertainty, VD visual disorder, MD motor dysfunction, CD communication deficit.
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QLQ-BN20 were high, although our subjects had various
types of brain tumors. These reliability coefficients are
higher than those reported in studies of the English [1]
and other language versions [4,6]. Our results suggest
that the QLQ-BN20 can be used to assess the HRQOL
in patients with other brain tumors as well as in those
with brain cancer.
Most of the item-subscale correlation coefficients in
the QLQ-C30 met the required convergent and discrim-
inant validity standards. This has not always been the
case; for example, the structures of the Mexican-Spanish
and Greek versions of the QLQ-C30 had weaknessesTable 4 Correlations between the Korean versions of the
QLQ-C30 and QLQ-BN20
C30-PF C30-RF C30-EF C30-CF C30-SF C30-QOL
BN20 - FU -.475* -.455* -.634* -.486* -.534* -.548*
VD -.319* -.340* -.367* -.447* -.282* -.348*
MD -.642* -.617* -.499* -.553* -.532* -.507*
CD -.379* -.396* -.388* -.511* -.410* -.378*
* Correlation is significant at the 0.01 level (2-tailed).
QLQ-C30 Quality of Life Core Questionnaire, QLQ-BN20 Quality of Life
Questionnaire Brain Cancer Module, PF physical functioning, RF role
functioning, EF emotional functioning, CF cognitive functioning, SF social
functioning, QOL quality of life; FU future uncertainty, VD visual disorder,
MD motor dysfunction, CD communication deficit.with respect to both their assessment of the cognitive
functioning scale and the nausea and vomiting item
[7-10]. In this study, we confirmed that the cognitive
functioning scale and the nausea and vomiting item were
improved as shown in an earlier study of Korean pa-
tients with cancer [3].
Most scores of the 2 instruments could clearly distin-
guish between patient groups according to performance
status as shown in earlier studies [4,6,10,11]. The second
hypothesis, that the 2 instruments could distinguish pa-
tients with glioma from those with meningioma, was par-
tially supported. A Chinese group [12] reported that most
scores of the EORTC-C30 were able to distinguish among
patients with different brain tumor types. However, they
did not compare differences of functioning, QOL and
symptoms among specific tumor types (e.g. glioma vs
meningioma) using a post-hoc test.
The third hypothesis, that the adjuvant treatment
group had greater future uncertainty than the group
who underwent surgery alone, was supported. This may
have been because the patients who received adjuvant
therapy after surgery perceived themselves to have more
severe disease than those who underwent surgery alone.
Finally, we confirmed that the construction validities
of the QLQ-BN20 and QLQ-C30 were acceptable, with
correlation coefficients values of r > 0.40. These results
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QLQ-BN20 and QLQ-C30 conducted for patients speaking
English [1], Persian [6], and 15 other languages [4].
The present study had some limitations. First, there
might have been sampling bias since all participants
were recruited from a single hospital and accurate sam-
ple size for this study was not calculated. Second, we did
not include responsiveness analysis because of the lack
of follow-up data. Therefore, these results should be
carefully interpreted and implemented.
In conclusion, our findings suggest that the Korean
versions of the EORTC QLQ-BN20 and QLQ-C30 are
clinically valid and reliable for measuring HRQOL and
are suitable for use in both clinical practice and clinical
studies, involving Korean patients with brain tumors.
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